AZN 250502 65.00P(AZN250502P65000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

AZN250502P65000

Watchlist

0.03
0.000.00%

15min DelayClose Apr 30 14:28 ET

0.10High0.01Low

Intraday

5D
Daily

News

AstraZeneca Price Target Lowered to 13,700 GBp at Morgan Stanley
TipRanks13:50 ET
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca Plc
MT NewswiresApr 30 10:35 ET · Ratings
AstraZeneca Considering Moving More Production to U.S., Pharmaphorum Reports
TipRanksApr 30 10:10 ET
Deutsche Bank Reaffirms Their Hold Rating on AstraZeneca (AZN)
TipRanksApr 30 07:56 ET · Ratings
AstraZeneca's Truqap Fails in Another Phase III Trial
Yahoo FinanceApr 30 07:06 ET
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating
Moomoo NewsApr 30 01:33 ET · Ratings

Comments

The World’s ATM

$AstraZeneca (AZN.US)$ should not buy u. all vaccine also banned next time.

1

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy

$AstraZeneca (AZN.US)$
First Major Breakthrough in 10 Years: ENHERTU Combo Outperforms Standard HER2+ Breast Cancer Treatment

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Posit

$AstraZeneca (AZN.US)$
First Major Breast Cancer Treatment Breakthrough in 10 Years: ENHERTU Trial Reveals Superior Efficacy

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Posit

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

$AstraZeneca (AZN.US)$
Revolutionary AI Technology Detects Lung Cancer Mutations Without Invasive Testing

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

$AstraZeneca (AZN.US)$
New Breast Cancer Drug DATROWAY Shows 37% Better Survival Rates in EU Approval

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Read more